← back to search

Enkhtsetseg Purev

University of Colorado Denver · US
Area of research
Hematology · Oncology
Research interest
Research interests include CAR-T cell therapy research, Lymphoma Diagnosis and Treatment, Acute Myeloid Leukemia Research, and Hematopoietic Stem Cell Transplantation.
h-index
26
citations
5,332
works
90
NIH funding
primary concept
Medicine
email

Recent publications

Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study
Blood Advances 2025cited by 10position: middledoi
Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001
Blood 2023cited by 159position: middledoi
Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study
Blood Advances 2023cited by 33position: middledoi
Priority Activities in Child and Adolescent Tuberculosis to Close the Policy-Practice Gap in Low- and Middle-Income Countries
Pathogens 2022cited by 24position: middledoi
Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)
Blood 2021cited by 56position: middledoi
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
The Lancet 2020cited by 2,295position: middledoi
Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas
Blood 2019cited by 115position: middledoi
Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network 2018cited by 281position: middledoi
Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL.
Journal of Clinical Oncology 2018cited by 168position: middledoi
NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017
Journal of the National Comprehensive Cancer Network 2016cited by 85position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

David G. Maloney · Fred Hutch Cancer Center5 papers (2018–2023)Jon Arnason · Harvard University5 papers (2018–2023)Alison R. Sehgal · UPMC Hillman Cancer Center5 papers (2018–2023)Charalambos Andreadis · UCSF Helen Diller Family Comprehensive Cancer Center5 papers (2018–2023)Nilanjan Ghosh · Wake Forest Baptist Comprehensive Cancer Center5 papers (2018–2023)Matthew A. Lunning · Alberta Cancer Foundation5 papers (2018–2023)Michael Wang · University of Guelph5 papers (2018–2023)Tanya Siddiqi · City Of Hope National Medical Center5 papers (2018–2023)Scott R. Solomon · Leukemia Research Foundation5 papers (2018–2023)Leo I. Gordon · Northwestern University5 papers (2018–2023)Amitkumar Mehta · University of Alabama4 papers (2019–2025)Yeonhee Kim · Seoul National University Hospital4 papers (2019–2023)Ana Kostić · CardioDx (United States)4 papers (2019–2023)Jeremy S. Abramson · Harvard University4 papers (2018–2023)Tina Albertson · Lyell Immunopharma (United States)3 papers (2018–2020)Jacob Garcia · Hospital General Universitario de Elche3 papers (2018–2020)M. Lia Palomba · Memorial Sloan Kettering Cancer Center3 papers (2020–2023)K. OGASAWARA · Bristol-Myers Squibb (United States)3 papers (2020–2023)Jason R. Westin · The University of Texas MD Anderson Cancer Center2 papers (2023–2025)Richard Greil · EB House Austria2 papers (2023–2025)